Some images has been designed using resources from Unsplash & Pixabay & Pexels & Freepik and some icons from Flaticon

陳明晃 (Ming-Huang Chen)


  • 學歷
    • 國立陽明大學 臨床醫學研究所 博士
    • 中國醫學大學 醫學系 醫學士
  • 經歷
    • 2021- 迄今 國立陽明交通大學 醫學系 內科學科 教授
    • 2020- 迄今 臺北榮民總醫院 腫瘤醫學部 腫瘤免疫治療中心 中心主任
    • - 迄今 臺北榮民總醫院 腫瘤醫學部 腫瘤內科 主治醫師
    • - 2021 國立陽明大學 醫學系 內科學科 副教授
    • - 國立陽明大學 醫學系 內科學科 助理教授
    • - 國立陽明大學 醫學系 內科學科 講師
    • - 臺北榮民總醫院 內科部 血液腫瘤科 主治醫師
    • - 臺北榮民總醫院 內科部 腫瘤科 住院總醫師
  • 醫療專長
    1. 腫瘤內科、腸胃道腫瘤(食道癌、胃癌、大腸直腸癌、膽管及胰臟癌)及神經內分泌腫瘤診斷及治療、臨床試驗發起及執行
  • 證照



  1. Chung SY, Chang YC, Hsu DS, Hung YC, Lu ML, Hung YP, Chiang NJ, Yeh CN, Hsiao M, Soong J, Su Y, Chen MH*. A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer. Neoplasia. 2023 Jan:35:100856. doi: 10.1016/j.neo.2022.100856. Epub 2022 Nov 25.
  2. Tang CY, Hang JF, Hung YP, Chiu NC, Lai JI, Chen MH, Liu CY, Yang MH, Chao Y, Chang PM. A generational comparison for unfavorable cancer of unknown primary in a single institute over 20 years. Cancer Med. 2023 Jan;12(2):1090-1101. doi: 10.1002/cam4.4960. Epub 2022 Jul 3.
  3. Wu CH, Lai CL, Teng CJ, Fang WL, Huang KH, Fen-Yau Li A, Yu HY, Chiang NJ, Chao Y, Hung YP, Chen MH*. Immunoprofile of adenosquamous carcinoma in gastric cancer. Neoplasia. 2023 Jan:35:100856. doi: 10.1016/j.neo.2022.100856. Epub 2022 Nov 25.
  4. Wu WC, Chen MH*. Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib. Front Oncol. 2023 Jan 10:12:1031396. doi: 10.3389/fonc.2022.1031396. eCollection 2022.
  5. Chiang NJ, Hou YC, Tan KT, Tsai HW, Lin YJ, Yeh YC, Chen LT, Hou YF, Chen MH, Shan YS. The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma. Hepatol Int. 2022 Oct;16(5):1137-1149. doi: 10.1007/s12072-022-10346-3. Epub 2022 Jul 3.
  6. Chiang NJ, Tan KT, Bai LY, Hsiao CF, Huang CY, Hung YP, Huang CJ, Chen SC, Shan YS, Chao Y, Huang YH, Lee IC, Lee PC, Su YY, Chen SJ, Yeh CN, Chen LT, Chen MH*. Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study. Clin Cancer Res. 2022 Oct 3;28(19):4248-4257.
  7. Wu WC, Lin TY, Chen MH, Hung YP, Liu CA, Lee RC, Huang YH, Chao Y, Chen SC. Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience. Invest New Drugs. 2022 Aug;40(4):789-797. doi: 10.1007/s10637-022-01248-0. Epub 2022 Apr 28.
  8. Lee JM, Chen MH, Chou KY, Chao Y, Chen MH, Tsai CY. Novel immunoprofiling method for diagnosing SLE and evaluating therapeutic response. Lupus Sci Med. 2022 Jun;9(1):e000693. doi: 10.1136/lupus-2022-000693.
  9. Chang YC, Li CH, Chan MH, Chen MH, Yeh CN, Hsiao M. Regorafenib inhibits epithelial-mesenchymal transition and suppresses cholangiocarcinoma metastasis via YAP1-AREG axis. Cell Death Dis. 2022 Apr 21;13(4):391. doi: 10.1038/s41419-022-04816-7.
  10. Chen SC, Huang YH, Chen MH, Hung YP, Lee RC, Shao YY, Chao Y. Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study. BMC Cancer. 2022 Jan 11;22(1):55. doi: 10.1186/s12885-022-09173-4.
  11. Hsu PK, Chien LI, Huang CS, Yeh YC, Huang PI, Chen MH, Chen SY, Yen CC, Hsu HS. Treatment Patterns and Outcomes in Patients with Esophageal Cancer: An Analysis of a Multidisciplinary Tumor Board Database. Ann Surg Oncol. 2022 Jan;29(1):572-585. doi: 10.1245/s10434-021-10568-z. Epub 2021 Aug 13.
  12. Yu HY, Li CP, Huang YH, Hsu SJ, Wang YP, Hsieh YC, Fang WL, Huang KH, Li AF, Lee RC, Lee KL, Wu YH, Lai IC, Yang WC, Hung YP, Wang YC, Chen SH, Chen MH, Chao Y. Microsatellite Instability, Epstein-Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer. Cancers (Basel). 2022 Jan 3;14(1):218. doi: 10.3390/cancers14010218.
  13. Chang YC, Chang PM, Li CH, Chan MH, Lee YJ, Chen MH, Hsiao M. Aldolase A and Phospholipase D1 Synergistically Resist Alkylating Agents and Radiation in Lung Cancer. Front Oncol. 2022 Jan 21:11:811635. doi: 10.3389/fonc.2021.811635. eCollection 2021.
  14. Chen MH, Lee IC, Chen MH, Hou MC, Tsai CY, Huang YH. Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease. Ann Rheum Dis. 2021 Nov;80(11):1393-1399. doi: 10.1136/annrheumdis-2021-220774. Epub 2021 Jun 29.
  15. Wu CH, Huang KH, Chen MH, Fang WL, Chao Y, Lo SS, Li AF, Wu CW, Shyr YM. Comparison of the Long-term Outcome Between Billroth-I and Roux-en-Y Reconstruction Following Distal Gastrectomy for Gastric Cancer. J Gastrointest Surg. 2021 Aug;25(8):1955-1961. doi: 10.1007/s11605-020-04867-1. Epub 2020 Nov 17.
  16. Chen MH, Wu CS, Chen MH, Tsai CY, Lee FY, Huang YH. High Risk of Viral Reactivation in Hepatitis B Patients with Systemic Lupus Erythematosus. Int J Mol Sci. 2021 Aug 24;22(17):9116. doi: 10.3390/ijms22179116.
  17. Chung SY, Hung YP, Pan YR, Chang YC, Wu CE, Hsu DS, Chang PM, Lu ML, Huang CF, Su Y, Hsiao M, Yeh CN, Chen MH. Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway. Biomedicines. 2021 Jul 24;9(8):885. doi: 10.3390/biomedicines9080885.
  18. Chen MH, Lu SN, Chen CH, Lin PC, Jiang JK, D'Yachkova Y, Lukanowski M, Cheng R, Chen LT. How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers?. Cancers (Basel). 2021 Jul 15;13(14):3536. doi: 10.3390/cancers13143536.
  19. Pai SM, Huang KH, Chen MH, Fang WL, Chao Y, Lo SS, Li AF, Wu CW, Shyr YM. Cardia Gastric Cancer Is Associated With Increased PIK3CA Amplifications and HER2 Expression Than Noncardia Gastric Cancer According to Lauren Classification. Front Oncol. 2021 Jun 8:11:632609. doi: 10.3389/fonc.2021.632609. eCollection 2021.
  20. Yang YC, Chien MH, Lai TC, Tung MC, Jan YH, Chang WM, Jung SM, Chen MH, Yeh CN, Hsiao M. Proteomics-based identification of TMED9 is linked to vascular invasion and poor prognoses in patients with hepatocellular carcinoma. J Biomed Sci. 2021 Apr 22;28(1):29. doi: 10.1186/s12929-021-00727-5.
  21. Chiang NJ, Chen LT, Shan YS, Yeh CN, Chen MH*. Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials. Biomolecules. 2021 Jan 13;11(1):97. doi: 10.3390/biom11010097.
  22. Cheng CT, Chen YY, Wu RC, Tsai CY, Chiang KC, Yeh TS, Chen MH*, Yeh CN*.  MET RON Dual Inhibitor, BMS 777607, Suppresses Cholangiocarcinoma Cell Growth, and MET RON Upregulation Indicates Worse Prognosis for Intra Hepatic Cholangiocarcinoma Patients. Oncol Rep 2018 Sep; 40(3): 1411-21. Epub 2018 Jul. (IF: 2.976; Oncology 123/222)

  23. Chang PM, Cheng CT, Wu RC, Chung YH, Chiang KC, Yeh TS, Liu CY, Chen MH, Chen MH*, Yeh CN*.  Nab-Paclitaxel is Effective against Intrahepatic Cholangiocarcinoma via Disruption of Desmoplastic Stroma. Oncol Lett 2018 Jul; 16(1): 566-72. Epub 2018 May. (IF: 1.664; Oncology 193/222)

  24. Yeh CN, Chang YC, Su Y, Shin-Shian Hsu D, Cheng CT, Wu RC, Chung YH, Chiang KC, Yeh TS, Lu ML, Liu CY, Mu-Hsin Chang P, Chen MH, Huang CF, Hsiao M*, Chen MH*.  Identification of MALT1 as Both a Prognostic Factor and a Potential Therapeutic Target of Regorafenib in Cholangiocarcinoma Patients. Oncotarget 2017 Dec; 8(69): 113444-59. (IF: 5.168; Oncology 44/217; Cell Biology 48/189)

  25. Lin LY, Yeh YC, Chu CH, Won JGS, Shyr YM, Chao Y, Li CP, Wang SE, Chen MH*.  Endocan Expression is Correlated with Poor Progression-Free Survival in Patients with Pancreatic Neuroendocrine Tumors. Medicine (Baltimore) 2017 Oct; 96(41): e8262. (IF: 1.803; Medicine, General & Internal 58/154)

  26. Chen MH, Weng JJ, Cheng CT, Wu RC, Huang SC, Wu CE, Chung YH, Liu CY, Chang MH, Chen MH, Chiang KC, Yeh TS, Su Y*, Yeh CN*.  ALDH1A3, the Major Aldehyde Dehydrogenase Isoform in Human Cholangiocarcinoma Cells, Affects Prognosis and Gemcitabine Resistance in Cholangiocarcinoma Patients. Clin Cancer Res 2016 Aug; 22(16): 4225-35. (IF: 8.738; Oncology 12/213)

  27. Chou WC, Lin PH, Yeh YC, Shyr YM, Fang WL, Wang SE, Liu CY, Chang PM, Chen MH, Hung YP, Li CP, Chao Y*, Chen MH*.  Genes Involved in Angiogenesis and mTOR Pathways Are Frequently Mutated in Asian Patients with Pancreatic Neuroendocrine Tumors. Int J Biol Sci 2016 Nov; 12(12): 1523-32. (IF: 3.982; Biochemistry & Molecular Biology 78/289)

  28. Chen MH, Lin J, Hsiao CF, Shan YS, Chen YC, Chen LT, Liu TW, Li CP*, Chao Y*.  A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed By Docetaxel Plus Capecitabine in Patients with Unresectable Gastric Adenocarcinoma: the TCOG 3211 Clinical Trial. Medicine (Baltimore) 2016 Jan; 95(3): e2565. (IF: 2.133; Medicine, General & Internal 40/155)

  29. Chen MH, Yen CC, Cheng CT, Wu RC, Huang SC, Yu CS, Chung YH, Liu CY, Chang PM, Chao Y, Chen MH, Chen YF, Chiang KC, Yeh TS, Chen TC, Huang CY, Yeh CN.  Identification of SPHK1 as a Therapeutic Target and Marker of Poor Prognosis in Cholangiocarcinoma. Oncotarget 2015 Sep; 6(27): 23594-608. (IF: 5.008; Oncology 36/213; Cell Biology 43/187)

  30. Chen MH, Kuo YJ, Yeh YC, Lin YC, Tzeng CH, Liu CY, Chang PM, Chen MH, Jeng YM, Chao Y*.  High Neuroendocrine Component is a Factor for Poor Prognosis in Gastrointestinal High-Grade Malignant Mixed Adenoneuroendocrine Neoplasms. J Chin Med Assoc 2015 Aug; 78(8): 454-9. Epub 2015 May. (IF: 1.013; Medicine, General & Internal 88/155)